title: Leveraging HIV treatment to end AIDS, stop new HIV infections, and avoid the cost of inaction.
abstract: We have the tools at our disposal to significantly bend AIDS-related morbidity and mortality curves and reduce human immunodeficiency virus (HIV) incidence. It is thus essential to redouble our efforts to reach the goal of placing 15 million people on life-saving and -enhancing antiretroviral therapy (ART) by 2015. In reaching this milestone, we can write a new chapter in the history of global health, demonstrating that a robust, multidimensional response can succeed against a complex pandemic that presents as many social and political challenges as it does medical ones. This milestone is also critical to advance our ultimate goal of ending AIDS by maximizing the therapeutic and preventive effects of ART, which translates into a world in which AIDS-related deaths and new HIV infections are exceedingly rare.
authors.affiliation: Joint United Nations Programme on HIV/AIDS, Geneva, Switzerland.
authors.forename: Michel
authors.initials: M
authors.lastname: Sidibé
authors.affiliation: International Association of Providers of AIDS Care, Washington, District of Columbia.
authors.forename: José M
authors.initials: JM
authors.lastname: Zuniga
authors.affiliation: British Columbia Centre of Excellence in HIV/AIDS, Vancouver, Canada.
authors.forename: Julio
authors.initials: J
authors.lastname: Montaner
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control*; D019380:Anti-HIV Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000517:prevention & control*; D006801:Humans
chemical_list: D019380:Anti-HIV Agents
keywords: HIV; antiretroviral therapy; prevention; testing; treatment